Weekly News Recap #Phispers
Novo bets up to US$ 4.6 bn on AI drug development, expands deal with Valo Health; WuXi sells Irish vaccine plant to Merck
As the embattled WuXi Biologics faces increasing pressure from the impending US Biosecure Act, it has decided to sell its vacci...
Impressions : 1218
Astra faces probe in China; AbbVie, EvolveImmune ink potential US$ 1.4 bn deal; EC levies US$ 503 mn fine on Teva
In this week’s Phispers, AstraZeneca faces a major crisis in China as its president Leon Wang is under investigation in w...
Impressions : 1152
BMS med wins landmark FDA nod for schizophrenia; Sanofi’s Dupixent approved to treat COPD
In this week’s Phispers, the US Food and Drug Administration (FDA) approved Bristol Myers Squibb’s groundbreaking s...
Impressions : 1388
IRA price talks conclude, three meds dominate savings; Gilead’s Livdelzi from CymaBay buyout gets FDA okay
This week, the Biden-Harris Administration said it has concluded price negotiations for 10 drugs under the Inflation Reduction ...
Impressions : 1120
Astra’s cancer drugs impress at ASCO; Moderna’s mRESVIA becomes first mRNA RSV vaccine approved by FDA
This week saw the American Society of Clinical Oncology (ASCO) annual meeting in Chicago where cancer researchers presented det...
Impressions : 1231
FDA okays Iovance’s cell therapy for skin cancer, issues warning letter to China’s Sichuan Deebio
The United States Food and Drug Administration (FDA) has granted accelerated approval to Iovance’s cell therapy — A...
Impressions : 1379
US Senator seeks “unannounced” FDA inspections; Nektar reports manufacturing issues with lead project
This week in Phispers, we bring you news about Nektar Therapeutics which disclosed declining efficacy of its lead project due t...
Impressions : 2690
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.